Interleukin-1β in circulating mononuclear cells predicts steatotic liver disease improvement after weight loss in subjects with obesity and prediabetes or type 2 diabetes
Authors' conclusion
In patients with obesity with initial impairment of glucose metabolism successful weight loss is associated with a reduction of both IL-1β levels and MASLD degree. Of interest, basal levels of IL-1β predict the extent of MASLD improvement, regardless of the intervention. Our results may set the stage for ad-hoc studies investigating the usefulness of baseline IL-1β a level as a drug-response biomarker.
Study context
- Population
- Obese subjects with prediabetes or newly diagnosed T2DObese subjects with prediabetes 16 · or newly diagnosed T2D 16
- Participants
- 32 subjects
- Comparison
- Liraglutide vs lifestyle counselling until comparable weight loss
- Primary endpoint
- Impact of equal weight loss on MASLD extent and IL-1β expression in peripheral blood mononuclear cells; whether baseline IL-1β predicts weight loss and metabolic changes
- Follow-up
- Achievement of weight loss target
Primary result
As reported in the abstract
after achievement of weight loss target
- Basal IL-1β independently predicted extent of MASLD decrease
- p = 0.030
- Median MASLD decrease, highest IL-1β tertile
- - 8.0 (95% CI - 12.3 to - 4.8)
- Median MASLD decrease, lowest IL-1β tertile
- - 23.0 (95% CI - 39.5 to - 16.3)
Further findings
Baseline correlations of IL-1β
- IL-1β positively correlated with body mass index (BMI), FPG, HbA1c, visceral adipose tissue (VAT), MASLD extent, platelet count, chemerin and IL1-RA
Original publication
Interleukin-1β in circulating mononuclear cells predicts steatotic liver disease improvement after weight loss in subjects with obesity and prediabetes or type 2 diabetes. Cardiovasc Diabetol. Published 13 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →